AFT hits US approval target, triggers cash

AFT hits US approval target, triggers cash
Managing director Hartley Atkinson said Maxigesic was an effective alternative for the US$700 million of IV paracetamol sold each year. (Photo: supplied).
Dan Brunskill
The United States medical regulator has accepted an application for AFT Pharmaceuticals’ patented pain relief medicine, which if approved would open up a more than US$300 million market.The US Food and Drug Administration has formally received the application for Maxigesic IV, an intravenous form of AFT’s painkiller, which was filed in August this year.Filing with the FDA triggers milestone payments worth US$3.6m under a licensing deal with US partner Hikma Pharmaceuticals. This will be recognised in the first half of the current fi...

More Markets

Reform wave reshapes energy sector as investors circle NZ
Infrastructure

Reform wave reshapes energy sector as investors circle NZ

Nearly half of surveyed offshore investors planning an acquisition.

Emissions intensity: Who’s clean, who’s carbon-heavy
Markets Carbon Catch-Up

Emissions intensity: Who’s clean, who’s carbon-heavy

Twenty-four companies with available data improved their emissions intensity.

WasteCo’s truck/toilet plan, Radius wants to grow West Coast
Markets Small Cap Wrap

WasteCo’s truck/toilet plan, Radius wants to grow West Coast

Plus: who got more money from investors, who tapped a twosome, and more.

Carrie Hurihanganui new Champions for Change co-chair
Markets

Carrie Hurihanganui new Champions for Change co-chair

The Auckland Airport CEO replaces ANZ’s Antonia Watson.